Chronic Kidney Disease (CKD) is often described as the invisible killer, mostly because patients have few or no symptoms until it is too late. On the practical level, this means that the disease, although devastating for both the individual and...
There is a large inequality of access to women's cancer services and treatments across the block, according to the EU health chief, who highlighted the role of Europe's Beating Cancer plan in bridging these disparities.
The much-awaited ‘Europe’s Beating Cancer Plan’ intends to create a knowledge centre to coordinate the scientific and technical cancer-related initiatives at the EU level, including the European health data space, according to a leaked draft of the plan.
The much-awaited 'Europe's Beating Cancer Plan' is being shaped with a strong push on prevention, targeting in particular alcohol and tobacco products, including novel tobacco products like e-cigarettes, EURACTIV has learnt.
A real strategy to tackle undernutrition, and not only obesity and overweight, should be implemented in the EU policy agenda in the wake of the revived cancer fight and COVID-crisis, several lawmakers have stressed in a recent virtual event.
Despite the solid evidence that outdoor workers in various workplaces across Europe are exposed to elevated levels of UV radiation and are consequently at a significantly increased risk of developing non-melanoma skin cancer (NMSC), this evidence has yet not been translated into a common European regulatory approach.
The much-awaited EU cancer plan will first have to identify specific needs at national level, seek funding and then be closely monitored in order to be successful, a high-ranking EU official has told EURACTIV.com.
The governments should take full responsibility for the implementation of national cancer plans, which are a commitment toward people and not just a piece of paper, health expert Dr Tit Albreht told EURACTIV.com in an interview.
With increased powers, Health Commissioner-designate Stella Kyriakides is tasked with striking a difficult balance between making sure there is a steady supply of affordable medicines and ensuring that EU pharma industry remains a world leader in innovation.